In Re Omeprazole Patent Litigation

Opinion

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

IN RE OMEPRAZOLE PATENT LITIGATION --------------------------------------------------------------------------

ASTRAZENECA AB, AKTIEBOLAGET HASSLE, KBI-E, INC., KBI, INC., AND ASTRAZENECA LP, Plaintiffs-Appellees,

v.

MYLAN LABORATORIES INC. (now known as Mylan Inc.), MYLAN PHARMACEUTICALS INC., LABORATORIOS DR. ESTEVE, S.A. and ESTEVE QUIMICA, S.A., Defendants-Appellants. ____________________

2010-1414 ______________________

Appeal from the United States District Court for the Southern District of New York in Nos. 00-CV-6749, 03- CV-6057, M-21-81, and MDL no. 1291, Judge Barbara S. Jones. ______________________

JUDGMENT ______________________

ERROL B. TAYLOR, Milbank, Tweed, Hadley & McCloy LLP, of New York, New York, argued for plaintiffs- appellees. With him on the brief were FREDRICK M. ZULLOW, JOHN M. GRIEM, JR., and CHRISTOPHER J. GASPAR. JAMES H. WALLACE, JR., Wiley Rein, LLP, of Washington, DC, argued for defendants-appellants. With him on the brief were MARK A. PACELLA and BRIAN H. PANDYA. ______________________

THIS CAUSE having been heard and considered, it is

ORDERED and ADJUDGED:

PER CURIAM (RADER, Chief Judge, MOORE and O’MALLEY, Circuit Judges).

AFFIRMED. See Fed. Cir. R. 36.

ENTERED BY ORDER OF THE COURT

March 8, 2011 /s/ Jan Horbaly Date Jan Horbaly Clerk